Nov 30, 2022 / 02:30PM GMT
Edward Andrew Tenthoff - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Great. Good morning, everyone. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before we begin, I'm required to point out certain disclosures regarding the relationship between Piper and our next presenting company, Alnylam, which are located at the back of the room and also at the registration desk.
So Alnylam is a leading developer of RNAi therapeutics. Now with four drugs approved and a rich pipeline of future therapies. Perhaps most important is the sNDA filing for ONPATTRO for hereditary and wild-type ATT amyloidosis with cardiomyopathy. In addition, I'm looking forward to ALN-APP data in the early onset Alzheimer's disease and also zilebesiran for hypertension data next year.
In addition, a fifth drug, Leqvio, has been approved, which is partnered with Novartis for high cholesterol, on which Alnylam receives royalty. Here today with us is CEO, Yvonne Greenstreet. Yvonne, thanks for being with us. It's always great to see you.
Yvonne L.
Alnylam Pharmaceuticals Inc at Piper Sandler Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers